Excision repair cross-complementation group 1 expression predicts response and survival in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy.
Zhe Long
ZL
Liang
Eun-Kee
EK
Song
Young Bok
YB
Ko
Na-Ri
NR
Lee
Ho-Young
HY
Yhim
Heung-Tae
HT
Noh
Hwan Jung
HJ
Yun
Kwang Sun
KS
Suh
Deog Yeon
DY
Jo
Samyong
S
Kim
Jun-Sang
JS
Kim
Jin Man
JM
Kim
Hyo Jin
HJ
Lee
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D059248:Chemoradiotherapy; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004268:DNA-Binding Proteins / Q000096:biosynthesis*; D004720:Endonucleases / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D002583:Uterine Cervical Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000628:therapy
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; C071447:ERCC1 protein, human; D004720:Endonucleases; D002945:Cisplatin